Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baucus Reform Framework Not So Taxing On Industry; $23 Bil. Is Fee-Based

Executive Summary

Senate Finance Committee Chairman Max Baucus' health care reform legislative framework includes a new proposal to raise revenue from the pharmaceutical industry - a $2.3 billion annual fee based on market share

You may also be interested in...



Donut Hole Discounts Would Cost Medicare $17.4 Bil.; AARP Wants Phase Out

The pharmaceutical industry proposal to provide 50 percent discounts on the price of branded drugs for Medicare Part D beneficiaries in the donut hole would wind up costing the federal government $17.4 billion over 10 years, according to estimates by the Congressional Budget Office and the Joint Committee on Taxation released Sept. 16

Donut Hole Discounts Would Cost Medicare $17.4 Bil.; AARP Wants Phase Out

The pharmaceutical industry proposal to provide 50 percent discounts on the price of branded drugs for Medicare Part D beneficiaries in the donut hole would wind up costing the federal government $17.4 billion over 10 years, according to estimates by the Congressional Budget Office and the Joint Committee on Taxation released Sept. 16

Baucus' Donut Hole Drug Discount Plan Would End Up Costing Medicare $17 Bil. Over 10 Years - CBO

Budget office score details costs and savings to Medicare under Sen. Baucus' "chairman's mark" of health reform legislation; discount's cost to pharma is twice as much.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel